Manufacturers development risks

In the next chapter, we introduce the concepts of component manufacturing capability and the relationships between tolerance, variability and cost. The Component Manufacturing Variability Risks Analysis is then introduced, the first stage of the CA methodology, from which process capability estimates can be determined at the design stage. The development of the knowledge and indices used in the analysis... 

Development of quantitative approach to safety problems in explosive storage and manufacturing plants (risk analysis)... 

The development of a VMP requires several decisions. If the facility is new, due consideration is given to determine, on time, the target dates for routine production to ensure completion of validation for facility approval otherwise manufacturing at risk is the alternative choice. The deadline determination provides ample opportunity to perform validation of utilities, critical equipment installation, and qualification prior to construction work. In addition, it provides a sufficient time frame to identify the critical processes and steps involved. The parameters critical for each step shall be established. The critical equipment required shall be determined. Critical processes, steps involved, parameters, and equipment are identified. For existing facilities, establish the criteria for revalidation based on known vulnerabilities and engineering projects in progress. 

For pharmaceutical development, risk may be associated with the technical challenges anticipated in developing a novel or complex drug delivery system or manufacturing process. Information from early preformulation and biopharmaceutics studies should indicate the potential problems for drug delivery, formulation development and manufacture. 

Several of FM s Loss Prevention Data Publications (1, 17B, 17C) discuss the concept of triply-redundant, fault-tolerant, high-reliability hardware/software systems for manufacturing operations. Risk analysis and systems reliability research is currently underway to develop better guidelines for the design and application of reliable process control systems. 

The project attracted interest of the Argentinean nuclear power utility and fuel manufacturing company and has been divided in three phases, in line with the growing complexity and costs and the reduced technology development risk. 

The development section serves as an intermediary between laboratory and industrial scale and operates the pilot plant. A dkect transfer from the laboratory to industrial-scale processes is stiH practiced at some small fine chemicals manufacturers, but is not recommended because of the inherent safety, environmental, and economic risks. Both equipment and plant layout of the pilot plant mirror those of an industrial multipurpose plant, except for the size (typically 100 to 2500 L) of reaction vessels and the degree of process automation. 

Arrester Testing and Standards Regulatory and approval agencies and insurers impose acceptance testing requirements, sometimes as part of certification standards. The user may also request testing to demonstrate specific performance needs, just as the manufacturer can help develop standards. These interrelationships have resulted in several new and updated performance test procedures. Listing of an arrester by a testing laboratoiy refers only to performance under a defined set of test conditions. The flame arrester user should develop specific application requirements based on the service involved and the safety and risk criteria adopted. 

In the development of the assembly variability risks analysis, expert knowledge, data found in many engineering references and information drawn from the CSC DFA/MA practitioner s manual (CSC Manufacturing, 1995) were collated and issues related to variability converged on. Much of the knowledge for the additional assembly variability risks analysis was reviewed from the fabrication and joining data sheets called PRocess Information MAps (PRIMAs) as given in Swift and Booker (1997). 

---